Boule Diagnostics AB (publ)

OM:BOUL Stock Report

Market Cap: SEK 344.8m

Boule Diagnostics Past Earnings Performance

Past criteria checks 0/6

Boule Diagnostics's earnings have been declining at an average annual rate of -21.9%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 6.1% per year.

Key information

-21.9%

Earnings growth rate

-17.1%

EPS growth rate

Medical Equipment Industry Growth6.2%
Revenue growth rate6.1%
Return on equity-83.4%
Net Margin-37.7%
Next Earnings Update11 Feb 2025

Recent past performance updates

Recent updates

Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified

Dec 03
Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified

Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?

Oct 10
Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?

Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Jul 25
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Jul 24
Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal

Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Jun 06
Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)

Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

May 10
Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Mar 20
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Feb 09
Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results

Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Dec 30
Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Jul 25
Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

May 26
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate

Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Jul 26
Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals

Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

Jul 19
Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)

We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Mar 06
We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt

Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

Feb 03
Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital

The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Apr 29
The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing

Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Apr 09
Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Mar 25
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Mar 07
Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend

Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

Feb 17
Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?

These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Jan 30
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively

Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

Jan 14
Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?

How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Dec 28
How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?

Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

Dec 10
Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate

What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Nov 22
What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?

Revenue & Expenses Breakdown

How Boule Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:BOUL Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24563-213164310
30 Jun 245732116249
31 Mar 245762715548
31 Dec 235712515353
30 Sep 235721914952
30 Jun 235581714850
31 Mar 235591614653
31 Dec 225481314452
30 Sep 225392713850
30 Jun 225253213148
31 Mar 224952812645
31 Dec 214632312043
30 Sep 21416-2711542
30 Jun 21403-1311342
31 Mar 21383-5510744
31 Dec 20400-4811143
30 Sep 20437-811641
30 Jun 20470-811937
31 Mar 204993513032
31 Dec 194993812830
30 Sep 194763212631
30 Jun 194562112433
31 Mar 194443611533
31 Dec 184244111029
30 Sep 184254811124
30 Jun 184246011225
31 Mar 184214311127
31 Dec 174283711632
30 Sep 174223111438
30 Jun 174212811038
31 Mar 174193810938
31 Dec 163973610537
30 Sep 16383369740
30 Jun 16364229642
31 Mar 16341159342
31 Dec 15331158940
30 Sep 15333299531
30 Jun 15318339126
31 Mar 15309338923
31 Dec 14307308824
30 Sep 14289148324
30 Jun 14285-688325
31 Mar 14287-648424
31 Dec 13277-708424

Quality Earnings: BOUL is currently unprofitable.

Growing Profit Margin: BOUL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BOUL is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare BOUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOUL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: BOUL has a negative Return on Equity (-83.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Boule Diagnostics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jakob LembkeABG Sundal Collier Sponsored
null nullABG Sundal Collier Sponsored
Christian LeePareto Securities